Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0001209191-24-003272 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-13 | 2024-02-09 | LYEL | Lee Gary K. | CSO | A - Grant | $0.00 | +40.0K | 52.7K | +315% | $0 |
| D | 2024-02-13 | 2024-02-09 | LYEL | Lee Gary K. | CSO | A - Grant | $0.00 | +400.0K | 400.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-09 | A | A | 40,000 | $0.00 | 52,700 | D | — | — | (F1) The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 4,702 shares acquired on November 18, 2022, 6,205 shares acquired on May 18, 2023 and 1,793 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan. |
| 2 | Derivative | Stock Option (right to buy) | 2024-02-09 | A | A | 400,000 | $0.00 | 400,000 | D | $1.80 · — to 2034-02-08 | 400,000 Common Stock | (F3) 12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months. |